GlassScriptPhysician profile
Mark K Eskandari
NPI 1790711729
$50,956.91
in general payments reported to CMS, 2019-2025
9 companies · $5,046 in 2025
The $5,046 reported for 2025 was more than what 84% of Vascular Surgery providers received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $2,627 · 2021: $1,840 · 2022: $20K · 2023: $4,589 · 2024: $4,696 · 2025: $5,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $1,177 · Travel and Lodging: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,805.00 |
| Food and Beverage | $1,177.30 |
| Travel and Lodging | $349.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $48,156.38 | 2019-2025 | Gore Excluder Iliac Branch Endoprosthesis, Gore Tag Conformable Thoracic Stent Graft, C3 Delivery System |
| Silk Road Medical, INC. | $2,329.92 | 2019 | |
| Bolton Medical INC | $289.47 | 2024-2025 | Relay Thoracic Stent-Graft With Plus Delivery System, Treo Abdominal Stent-Graft System |
| Abiomed | $84.36 | 2023 | Impella |
| Angiodynamics, INC. | $53.11 | 2025 | Smart Port Ct |
| Limflow INC. | $43.67 | 2023 | Limflow System |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Eskandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.